Health Care & Life Sciences » Pharmaceuticals | CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc. | Ownership

Companies that own CymaBay Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Baker Bros. Advisors LP
4,917,700
8.33%
1,000,000
0.44%
06/30/2018
BlackRock Fund Advisors
3,722,071
6.3%
2,849,568
0%
06/30/2018
Redmile Group LLC
2,957,765
5.01%
2,200
1.25%
06/30/2018
Perceptive Advisors LLC
2,742,821
4.63%
-60,000
0.85%
06/30/2018
The Vanguard Group, Inc.
2,574,451
4.36%
49,315
0%
06/30/2018
Adage Capital Management LP
2,475,000
4.19%
-1,000,000
0.07%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
2,094,000
3.55%
-618,986
1.96%
06/30/2018
Eagle Asset Management, Inc.
2,063,066
3.49%
2,063,066
0.13%
06/30/2018
Citadel Advisors LLC
1,914,807
3.24%
846,407
0.03%
06/30/2018
Franklin Advisers, Inc.
1,798,700
3.05%
0
0.02%
06/30/2018

About CymaBay Therapeutics

View Profile
Address
7575 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.cymabay.com
Updated 07/08/2019
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.